Phase 3 Readout~month

Phase 3 Topline: A Phase III, Randomized, Double-blind, Active Controlled Clinical Trial to Evaluate the Immunogenici

Indication
Pneumococcal Infectious Diseases

Other upcoming events for SVA

Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicit
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicit
Phase 3 ReadoutPhase 3 Topline: A Multicenter, Randomized, Double-Blind, Active-Controlled Phase Ⅲ Clinical Trial to Evaluate the Ef
Phase 3 ReadoutPhase 3 Topline: A Phase III, Randomized, Double-blind, Active Controlled Clinical Trial to Evaluate the Immunogenici
Phase 3 ReadoutPhase 3 Topline: A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicit

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase III, Randomized, Double-blind, Active Controlled Clinical Trial to Evaluate the Immunogenici — SVA Phase 3 Readout | BioSniper